Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBS-1 intranasal testosterone gel dispenser versus syringe pharmacokinetic crossover pilot study
NL-OMON36214Phase 1Active, not recruiting
- Sponsor
- Trimel Pharmaceuticals
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of natesto in Hypoandrogenism (TD) (2 arms), sponsored by Trimel Pharmaceuticals. Primary endpoints: Testosterone pharmacokinetic profile over 12 hours and Relative bioavailability comparison. Started Mar 2011; status: active, not recruiting.
02
Drugs
natesto
03
Conditions
Hypoandrogenism (TD)
Beyond the preview
Go deeper on NL-OMON36214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36214.